United Therapeutics traded at $220.90 this Thursday August 18th, decreasing $0.73 or 0.33 percent since the previous trading session. Looking back, over the last four weeks, United Therapeutics lost 4.55 percent. Over the last 12 months, its price rose by 9.87 percent. Looking ahead, we forecast United Therapeutics to be priced at 211.02 by the end of this quarter and at 193.79 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
220.37
Daily Change
-0.57%
Yearly
9.61%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Amarin 1.57 -0.06 -3.68% -70.98%
Ardelyx 1.07 -0.01 -0.93% -18.94%
Baxter International 60.39 -0.99 -1.61% -19.50%
Bayer 54.06 0.69 1.29% 13.46%
BioCryst Pharmaceuticals 14.24 -0.01 -0.09% -0.02%
Biogen 214.90 -2.68 -1.23% -36.54%
BioMarin Pharmaceutical 93.74 -1.10 -1.16% 25.37%
Emergent BioSolutions 28.24 -0.19 -0.67% -53.74%
Esperion Therapeutics 7.05 0.05 0.64% -46.39%
Gilead Sciences 64.74 -1.28 -1.94% -9.67%
GlaxoSmithKline 1,402.00 -13.40 -0.95% -7.37%
Halozyme Therapeutics 42.11 -1.30 -2.99% 9.46%
Intercept Pharmaceuticals 18.21 -0.52 -2.78% 31.58%
Insmed 25.75 -0.02 -0.08% 14.65%
Ionis Pharmaceuticals 44.00 0.12 0.27% 16.28%
Intra Cellular Therapies 51.48 -0.02 -0.04% 79.25%
J&J 166.05 -1.53 -0.91% -7.01%
Lexicon Pharmaceuticals 3.07 0.01 0.16% -10.38%
Moderna Inc 150.64 -7.36 -4.66% -59.89%
Omeros 6.14 -0.49 -7.39% -55.41%
Pfizer 48.39 -0.88 -1.79% -0.84%
PTC Therapeutics 51.26 0.09 0.18% 38.50%
Regeneron Pharmaceuticals 626.89 -9.45 -1.49% -4.38%
Seattle Genetics 169.88 -0.91 -0.53% 7.46%
Sangamo BioSciences 5.88 -0.01 -0.17% -34.74%
Sarepta Therapeutics 108.83 -0.17 -0.16% 47.13%
Teva Pharmaceutical Industries Ltd 3,275.00 -17.00 -0.52% 6.92%
United Therapeutics 220.37 -1.26 -0.57% 9.61%
Vertex Pharmaceuticals 293.23 -6.00 -2.01% 50.34%

Indexes Price Day Year
USND 12943 4.79 0.04% -11.00%
US400 2607 7.50 0.29% -1.42%

United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. The Company market and sell four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution, which includes the Tyvaso Inhalation System; Orenitram (treprostinil) Extended-Release Tablets; and Adcirca (tadalafil) Tablets. In the United States, the Company also markets and sells an oncology product, Unituxin (dinutuximab) Injection, which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion.